Source-grounded facts extracted from Humacyte, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Humacyte, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“May 4, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended May 1, 2026, th”
Humacyte, Inc. amended Third Amendment to Distribution Agreement with Fresenius Medical Care Holdings, Inc. valued at low-single-digit royalties on net sales (effective 2026-04-21).
“On April 21, 2026, Humacyte, Inc. (the “Company”) entered into the Third Amendment to Distribution Agreement (the “Amendment”) with Fresenius Medical Care Holdings, Inc. (“Fresenius”), to amend the Distribution Agreement, dated as of June 25, 2018, as amended, between the Company and Fresenius (the “Agreement”).”
Humacyte, Inc. entered into Placement Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2026-03-19).
“On March 19, 2026, the Company also entered into a placement agent agreement (the “Placement Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as the placement agent (the “Placement Agent”), in connection with the Offering.”
Humacyte, Inc. entered into Purchase Agreements with certain investors valued at 25,000,000 shares ... at a price of $0.80 per share (effective 2026-03-19).
“On March 19, 2026, Humacyte, Inc. (the “Company”) entered into certain securities purchase agreements (the “Purchase Agreements”) pursuant to which the Company agreed to issue and sell to certain investors in a registered direct offering (the “Offering”) 25,000,000 shares of the Company’s common stock, $0.0001 par value per share, at a price of $0.80 per share (the “Shares”).”
Humacyte, Inc. incurred term loan of $77,500,000 with Avenue Venture Opportunities Fund II, L.P. at greater of (i) 11.50% and (ii) the sum of the Wall Street Journal Prime Rate plu maturing December 1, 2029.
“On December 15, 2025 (the "Closing Date"), Humacyte, Inc. (the "Company") and Humacyte Global, Inc. ("Global", and together with the Company, the "Borrowers"), a wholly-owned subsidiary of the Company, entered into a loan and security agreement (the "Loan Agreement") with Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders (the "Loan Agent") and as lender ("Avenue"), which provides for a senior secured term loan facility of up to $77,500,000 in the aggregate that matures on December 1, 2029, consisting of (i) an initial term loan of $40 million (the "First Tranche Term Loan"), which was fully funded on the Closing Date, (ii) a $12.5 million delayed draw term loan (the "Second Tranche Term Loan") which will be made available between October 1, 2026 and March 31, 2027, subject to the satisfaction of certain revenue, regulatory approvals and liquidity conditions, and (iii) a $25 million delayed draw term loan (the "Third Tranche Term Lo”
Humacyte, Inc. amended debt with TPC Investments III LP and TPC Investment Solutions LP.
“ith TPC Investments III LP and TPC Investment Solutions LP (collectively, the “Purchasers”) and Hook SA LLC, as agent for”
Humacyte, Inc.: Increased authorized shares of common stock from 250,000,000 to 350,000,000 (effective 2025-06-10).
“At the Annual Meeting, upon the recommendation of the Company’s board of directors, the Company’s stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock from 250,000,000 to 350,000,000 (the “Amendment”). The Amendment became effective upon the filing thereof with the Secretary of State of the State of Delaware on June 10, 2025.”
Humacyte, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 10, 2024, Humacyte, Inc. issued a press release regarding its financial results for its fiscal first quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.